Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro
- 1 April 1999
- journal article
- Published by Elsevier in Immunopharmacology
- Vol. 41 (3) , 227-234
- https://doi.org/10.1016/s0162-3109(99)00035-1
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998
- Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavirInternational Journal of Clinical Pharmacy, 1997
- The SWISS-PROT protein sequence data bank and its supplement TrEMBLNucleic Acids Research, 1997
- Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agentsProtein Science, 1996
- The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitorsStructure, 1995
- L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease InhibitorJournal of Medicinal Chemistry, 1994
- PUTATIVE VIRULENCE FACTORS OF CANDIDA ALBICANSAnnual Review of Microbiology, 1991
- Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motifTrends in Biochemical Sciences, 1991
- Oral Candidiasis in High-Risk Patients as the Initial Manifestation of the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1984
- Flow cytometric assay for combined measurement of phagocytosis and intracellular killing of Candida albicansJournal of Immunological Methods, 1984